Preterm birth is frequently accompanied by significant medical problems, including bronchopulmonary dysplasia, retinopathy of prematurity, and infection ([@bib1],[@bib2],[@bib3]). These complications are inversely proportional to gestational age at birth. Many of these morbidities are the result of hemodynamic instability, cardiovascular dysfunction and hypotension, and they are correlated with increased mortality and morbidity ([@bib4]). The association of these problems with hypothalamic-pituitary-adrenal (HPA) function and dysregulation has been investigated intensively in preterm infants; these illnesses impact cortisol levels of preterm infants at discharge ([@bib5],[@bib6],[@bib7]). Although there are no accepted "normal" levels of circulating cortisol in preterm infants, these infants have lower cortisol levels at discharge relative to full-term infants ([@bib8]), and critically ill preterm infants show even lower cortisol levels than healthy preterm infants ([@bib4]). Decreased cortisol levels can attenuate response to illnesses associated with prematurity by modulating the secretion of corticotropin-releasing hormone ([@bib4],[@bib9]).

Cortisol levels are regulated by the cross-talk of a sensitive feedback loop between the hormone products of the hypothalamus, pituitary, and adrenal gland. There are complex mechanisms for the regulation of hormone and hormone receptor expression and processing. A widely studied example is the regulation of cortisol responsiveness by epigenetic changes in glucocorticoid receptor gene (*NR3C1*) expression. In rodents, increased maternal care is associated with decreased DNA methylation, increased expression of hippocampal *NR3C1*, and decreased HPA responses to stress (lower levels of corticosterone) ([@bib10]). In one study, human infants born to mothers with high prenatal stress demonstrated increased methylation of the *NR3C1* promotor region, creating the potential for adult-onset disease ([@bib11]). DNA methylation of the *NR3C1* promoter in placenta has also been related to newborn neurobehavioral outcome ([@bib12]). Maternal depression during pregnancy is also related to increased methylation of *NR3C1* in this region ([@bib12],[@bib13]). However, decreased methylation of *NR3C1* in this region is related to maternal smoking during pregnancy ([@bib14]) and to worse newborn neurobehavior ([@bib15]). In preterm infants, the postnatal environment has been shown to influence methylation of *NR3C1*, possibly affecting cortisol regulation ([@bib16]). These results suggest that epigenetic mechanisms could play a role in the regulation of cortisol levels in preterm infants. To our knowledge, there are no studies of the association of epigenetic alterations in preterm infants with postnatal medical morbidities that could directly affect their neuroendocrine system function. The purpose of this exploratory study was to examine whether there are differences in DNA methylation in the promoter region 1F of *NR3C1* in preterm infants with varying levels of medical acuity before discharge from the Neonatal Intensive Care Unit (NICU).

Results
=======

Complete data were available for 63 infants. Infants in the high-risk medical cluster (*n* = 38) had more medical problems than infants in the low-risk medical cluster (*n* = 25) (**[Table 1](#tbl1){ref-type="table"}**). There were statistically significant differences between the two clusters on 31 of the 36 medical variables. The 36 medical variables include Neonatal Therapeutic Intervention Scoring System (NTISS) scores and several other clinical variables. Of note, eight out of the nine illness severity components of the NTISS score were significantly different between the two clusters. Likewise, among the major morbidities of prematurity, bronchopulmonary dysplasia and retinopathy of prematurity were significantly more common in the high-risk medical cluster than in the low-risk medical cluster while intraventricular hemorrhage and necrotizing enterocolitis were not. Thirteen out of the 15 treatments/interventions were used significantly more often in the high-risk medical cluster than in the low-risk medical cluster. A correlation matrix was generated to provide insight into the interrelationships of these variables (**[Figure 1](#fig1){ref-type="fig"}**). Attesting to the homogeneity of the patients enrolled, there were no statistically significant differences between the two clusters on demographic characteristics (**[Table 2](#tbl2){ref-type="table"}**). The population demographic results shown closely match the 2010 Rhode Island census ([@bib17]), reflecting the population-based nature of our clinical services.

The average % methylation at individual CpG sites 1-4 was analyzed and compared (**[Table 3](#tbl3){ref-type="table"}**, **[Figure 2](#fig2){ref-type="fig"}**). A Mann-Whitney *U*-test showed a lower mean percent methylation at CpG1 for infants in the high-risk cluster (M = 0.336, SE = 0.084) than infants in the low-risk cluster (M = 0.617, SE = 0.109, *P* = 0.032). The false discovery rate was low (q = 0.025). The Cohen D effect size was moderate (0.525).

Discussion
==========

We found that preterm infants with more medical problems had a lower level of DNA methylation of the *NR3C1* exon 1F promoter region at CpG1 than infants with fewer medical problems. It is likely that these differences represent subpopulations of cells within our samples exhibiting differential methylation, and within those cells lead to functional changes in the expression of this gene. The proximal promoter of the *NR3C1* gene has been widely studied in rodents ([@bib10]) and its homolog region of the human infant ([@bib11],[@bib13]). This region contributes to regulation of the neuroendocrine system including the HPA axis and stress reactivity. CpG sites 1-4 were selected for this study based on animal and human studies of DNA methylation of *NR3C1*. This includes the original work of Weaver *et al*. ([@bib10]) and later human studies by Oberlander *et al*. ([@bib13]) and others. These sites are particularly important because they are binding sites for a number of important transcription factors that regulate the expression of the *NR3C1* gene such as NGF1-A (nerve growth factor) that is important for brain development ([@bib18]). By contrast, in humans, little is known about the more distal sites making any differences between the high and low risk infants at these sites difficult, at best, to understand.

CpG1 is a binding site for the heat shock factor (HSF), p300, and ADR1 (alcohol dehydrogenase regulator) transcription factors (**[Figure 3](#fig3){ref-type="fig"}**). HSF upregulates genes in the heat shock pathway and other cellular stress responses, allowing for the mitigation of damage when a cell undergoes thermal stress and protects neurons from death caused by the misfolding of proteins ([@bib19]). Heat shock factors lead to the activation of genes responsible for protecting the cell from various cellular and physiologic stressors, which may be particularly important in this population of preterm infants ([@bib20]). Given the many medical morbidities in preterm infants, it is plausible that a more robust heat shock response would be accompanied by more HSF binding to *NR3C1* at CpG1. Thus decreased methylation of CpG1in the high medical risk group may mediate a more active heat shock response, increasing transcriptional activation of the *NR3C1* gene. p300 is important for the regulation of cell growth and division, as well as maturation and differentiation ([@bib21]). This transcription factor has been shown to play an important role in tumor suppression and cell proliferation or apoptosis ([@bib22]). ADR1 is involved in the regulation of glucose metabolism ([@bib23]). Our results may suggest that p300 and ADR1 may also be more active in the higher medical risk group. This may be important in this population at risk for illnesses associated with deviations from the normal developmental trajectory. Thus, we speculate that CpG1 may be involved in the response to illness and mediating protective adaptations, including altered glucocorticoid receptor expression.

We also speculate that the difference in DNA methylation that we found between infants with more vs. fewer medical problems promotes adaptive programming. In the sicker infants, lower methylation of the *NR3C1* promotor would lead to greater expression of glucocorticoid receptor, giving rise to a greater feedback suppression of adrenocorticotropic hormone (ACTH) release when the glucocorticoid receptor is occupied by circulating cortisol levels. Many of the morbidities in infants with high medical risk impact the neuroendocrine system and the number of medical morbidities is likely to lead to cumulative stress to the neuroendocrine system. The combination of these two factors over the course of a lengthy stay in high medical risk infants could result in a less responsive or underactive HPA axis. This can be a form of chronic stress for these infants and there is substantial literature showing that chronic stress results in an underactive HPA system with long-term deleterious consequences ([@bib24],[@bib25]). In addition, decreased *NR3C1* promoter DNA methylation in the infants with more medical problems may allow for increased binding of the HSF, p300, and ADR1 transcription factors that are involved in stress response and repair ensuring and regulating healthy growth, which could be a physiological priority over increasing cortisol levels. Our results show that methylation of CpG1 is greater in low risk infants compared to high risk infants with more medical problems. As healthier preterm infants recover and approach discharge from the NICU, altered programming of the neuroendocrine system could result in an increase in cortisol to more normal levels ([@bib2],[@bib3],[@bib4]). We predict that over time, as the high medical risk infants recover, we would see a shift in methylation patterns toward increased methylation as seen in the low medical risk group.

This study has strengths and limitations. It is novel data among a group of extremely ill, but well-phenotyped, patients. The analytical approach has been previously validated by ourselves and others. Nonetheless, we did not measure cortisol levels. Therefore, we lack *direct* evidence that cortisol levels differed between the two groups. Second, exogenous dexamethasone was given to 29% of the infants in the group with more medical problems and was not used at all in the group with fewer medical problems. This is not surprising since 68% of the infants with more medical problems had bronchopulmonary dysplasia. Third, the percent methylation values of all sites were low, below 1%, similar to those levels we and others have seen in prior human studies using accessible samples ([@bib13],[@bib26],[@bib27]). That said, we are pointing to the differences between the methylation levels in the two medical risk groups rather than the levels themselves. In fact, low levels of methylation of *NR3C1* are the norm for the CpG sites more proximal to the promoter. The magnitude of methylation is not related to the presumed importance of specific regions of the gene. Little is known about the meaning of methylation levels at the more distal sites in humans, even though these are the sites with higher methylation levels. Finally, this study was, in part, exploratory. We did not hypothesize the direction of effects. We did, however, hypothesize differences in the CpG 1-4 region.

Important new studies are needed to clarify the implications of our results beyond just the measurement of neonatal cortisol levels. What are the levels of ACTH, Dehydroepiandrosterone (DHEA), and other important hormones? Most importantly, what is the level of HPA reactivity? Adrenal stimulation tests, with and without basal ACTH levels, have been widely used to identify adrenal insufficiency in the NICU ([@bib5]). Such testing of HPA function including a combination of assessment of basal and stimulated cortisol production and comparison with *NR3C1* promoter methylation would clarify the role of these mechanisms in early programming and perhaps risk of life-long disease ([@bib28]).

Conclusion
----------

This study of preterm infants shows that medical factors are related to DNA methylation of the *NR3C1* promoter. This alteration may regulate cortisol levels. If so, this mechanism may be responsible for the observed differences in cortisol levels related to medical problems in preterm infants. These results contribute to our understanding of the consequences of prematurity. DNA methylation of *NR3C1* has been studied in many populations and has been shown to be related to newborn neurobehavior ([@bib29]), cortisol reactivity in infants ([@bib13]), environmental adversity (parenting) ([@bib30],[@bib31]), childhood psychopathology, maltreatment, and suicide ([@bib32]). It is well documented that preterm infants are at increased risk for later neurodevelopmental and cognitive impairment ([@bib33],[@bib34]) and behavior disorders ([@bib35],[@bib36],[@bib37]). Thus, our findings could have implications for the long-term development of preterm infants and provide additional understanding of epigenetic activity related to neonatal medical risk that may have longer-term consequences.

Methods
=======

The sample included 63 infants born \<1,500 g enrolled within 2 wk of hospital discharge from the NICU at Women & Infants Hospital of Rhode Island. Exclusion criteria included; non-English speaking or \<18-y-old mother, infant congenital anomalies, or transfer. The hospital institutional review board approved the study, and written informed consent was obtained from all participants.

Medical Outcomes
----------------

Medical outcomes and demographic data were prospectively defined using definitions from the NICHD Neonatal Research Network. Data were abstracted from the hospital electronic database. These included birth weight, discharge weight, birth GA, discharge gestational age (GA), mean weekly weight gain, length of stay, head circumference at birth, head circumference at discharge, total change in head circumference, intraventricular hemorrhage, bronchopulmonary dysplasia, necrotizing enterocolitis, and retinopathy of prematurity. Additionally, the use of any of the following treatments were recorded: mechanical ventilation, high-frequency ventilation, surfactant administration, endotracheal intubation, diuretic administration, phlebotomy, arterial pressure monitoring, red blood cell transfusion, thoracentesis, minor operation, arterial line, and use of a central venous line. The NTISS is a measure of therapeutic intensity and provides an index of neonatal illness severity and resource utilization throughout length of stay in the NICU. The NTISS scores were used to assess illness severity and medical interventions ([@bib38]). After normalizing each row for NTISS scores and the clinical data in the matrix, we illustrated the inter-relationships between the clinical data, the illness severity scores, and the NTISS scores. **[Figure 2](#fig2){ref-type="fig"}** demonstrates the correlation of the clinical data and NTISS scores with each other. In order to visualize this correlation, we used the corrplot package in the R program.

DNA Methylation Analysis
------------------------

Genomic DNA was extracted from buccal epithelial cells collected just prior to discharge from the NICU using Oragene Discover for assisted collection using the prepIT kit (DNA Genotek, (Kanata, Ontario, Canada), and subjected to bisulfite modification using the EZ DNA methylation Kit (Zymo Research, Irvine, CA). Pyrosequencing was performed on PCR product amplified from bisulfite modified DNA as described previously ([@bib39]). The primers for amplification were Forward: 5′-TTTTTTTTTT GAAGTTTTTT TA-3′ and Reverse: 5′-Biotin-CCCCCAACTC CCCAAAAA-3′. The sequencing primer was designed to sequence the first five CpG sites (5′-GAGTGGGTTT GGAGT-3\'). Percent DNA methylation at each CpG site was quantified using the Pyro Q-CpG software, version 1.0.11 (Qiagen, Valencia, CA). Bisulfite conversion controls were included with each sequencing run. In order for the sample\'s DNA methylation extent to be called, the bisulfite conversion rate must be \>93%, and for all samples examined the conversion rate was \>95%. All samples were sequenced in triplicates from the same bisulfite converted DNA template, and if the repeats differed by \>10% the sample was repeated.

Statistical Methods
-------------------

One-way ANOVA was used for continuous medical and demographic variables, χ2 for dichotomous variables. A Mann-Whitney *U*-test was used for methylation variables, which were not normally distributed. Cluster analysis (SPSS Cluster Analysis) was used to group the infants into mutually exclusive groups based on medical problems. Given the estimated models, the model with the lower value of Bayesian Information Criterion is the one to be preferred. Both continuous and categorical variables can be used with this type of algorithm. The cluster analysis resulted in two categories based on Bayesian Information Criterion (**[Table 4](#tbl4){ref-type="table"}**). The Benjamini and Hochberg method (false discovery rate, q \< 0.10) was used to determine the percent of findings that could be a false discovery ([@bib40]). Since this was, in part, an exploratory study, we used a q of 0.10, which is conservative but not stringent.
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###### Model fit statistics for the cluster analysis
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###### Demographic characteristics of infants in the high medical risk and low medical risk groups
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###### Mean percent methylation at *NR3C1* CpG sites 1-4 for infants in the high medical risk and low medical risk groups
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###### Medical characteristics of infants in the high medical risk and low medical risk groups
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